Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
MARCH 2024
Trastuzumab Q2 2024 ASP Report
Aria analytics
Aria is dedicated to enhancing value for our members through cutting-edge analytics and business intelligence solutions. With this objective, our team has compiled a report to assist members in understanding the product landscape, visualizing ASP trends, and anticipating future ASPs for key products.
Our goal is to empower members with clear insights, enabling well-informed purchasing decisions and the development of sustainable, long-term strategies.
The
© 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
Copyright
no
warranties regarding, the content,
completeness of the
the
property rights to any pharmaceutical product
content provided in this material is for informational purposes only and is not intended as legal advice or to replace a medical provider’s judgment. All information used in this material has been sourced from publicly available sources. Aria GPO “Aria” does not endorse or approve, assumes no responsibility for, and makes
representations nor
accuracy or
information presented. Aria GPO does not own
intellectual
mentioned herein.
Table of contents
• Product comparison
• Average Sales Prices Q1 2024 & Q2 2024
• Reimbursement information for Q2 2024
• Historical ASPs
• Average Change of ASP
• WAC vs. Initial ASPs
• ASP Percent Change from WAC
• Aria ASP predictive model
The content provided in this material is for informational purposes only and is not intended as legal advice or to replace a medical provider’s judgment. All information used in this material has been sourced from publicly available sources. Aria GPO “Aria” does not endorse or approve, assumes no responsibility for, and makes no representations nor warranties regarding, the content, accuracy or completeness of the information presented. Aria GPO does not own the intellectual property rights to any pharmaceutical product mentioned herein.
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
Product comparison
Product Strength & Dosage
Herceptin1 (Genentech)
Ogviri2 (Biocon)
Injection: Single-dose vial 150mg lyophilized powder.
Injection: Single-dose vial 150 mg lyophilized powder.
Injection: multiple-dose vial 420 mg lyophilized powder.
Injection: multiple-dose vial with diluent 420mg lyophilized powder.
Treatment Cold Chain
Adjuvant Breast Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer
Yes
Kanjinti3 (Amgen)
Trazimera4 (Pfizer)
Herzuma5 (Cephalon)
Ontruzant6 (Organon)
Injection: Single-dose vial 150 mg lyophilized powder.
Injection: multiple-dose vial 420mg lyophilized powder.
Injection: Single-dose vial 150mg preservative-free lyophilized powder. Injection: multiple-dose vial 420mg preservative-free lyophilized powder
1. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ebf30894-41cf-480c-8bc3-56f592a13813
2. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6465b44-a6dd-f99c-d009-6851cf05169c 3. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9a94f5b2-b84e-4987-8ea1-c4346db5a5fa 4. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b9c5e894-27d2-4245-a653-df986fed3c56
5. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae71c003-883a-4cd8-ad50-e8cc9a54e971 6. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ce2a2492-85e3-4b0a-872a-047f44e4203d
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
Average Sales Prices Q1 2024 & Q2 2024 (150mg)
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
Product WAC Previous ASP New ASP % Change Biologic Herceptin (Genentech) $1,558.42 $1,138.66 $1,132.75 -0.52% Biosimilar Ogivri (Biocon) $940.51 $575.33 $848.65 47.51% Kanjinti (Amgen) $1,360.07 $110.65 $174.59 57.79% Trazimera (Pfizer) $1,211.10 $154.41 $100.85 -34.68% Herzuma (Cephalon) $1,402.50 $513.51 $746.33 45.34% Ontruzant (Organon) $1,324.66 $492.95 $420.23 -14.75% -0.52% 47.51% 57.79% -34.68% 45.34% -14.75% $0 $200 $400 $600 $800 $1,000 $1,200 Herceptin (Genentech) Ogivri (Biocon) Kanjinti (Amgen) Trazimera (Pfizer) Herzuma (Cephalon) Ontruzant (Organon) ASP Change Previous ASP New ASP
Average Sales Prices Q1 2024 & Q2 2024 (420mg)
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
Product WAC Previous ASP New ASP % Change Biologic Herceptin (Genentech) N/A N/A N/A N/A Biosimilar Ogivri (Biocon) $2,625.05 $1,610.92 $2,376.22 47.51% Kanjinti (Amgen) $3,808.18 $309.84 $488.86 57.79% Trazimera (Pfizer) $3,391.08 $432.36 $282.39 -34.68% Herzuma (Cephalon) $3,927.00 $1,437.84 $2,089.74 45.34% Ontruzant (Organon) $3,709.04 $1,380.25 $1,176.66 -14.75% 47.51% 57.79% -34.68% 45.34% -14.75% $0 $500 $1,000 $1,500 $2,000 $2,500 Ogivri (Biocon) Kanjinti (Amgen) Trazimera (Pfizer) Herzuma (Cephalon) Ontruzant (Organon) ASP Change Previous ASP New ASP
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential. Reimbursement information
Product Launch Date HCPC WAC ASP Anticipated Medicare Reimbursement* Biologic Herceptin (Genentech) 1/31/2009 J9355 $1,558.42 $1,132.75 $1,181.51 Biosimilars Ogivri (Biocon) 12/31/2019 Q5114 $940.51 $848.65 $924.24 Kanjinti (Amgen) 10/31/2019 Q5117 $1,360.07 $174.59 $260.97 Trazimera (Pfizer) 3/31/2021 Q5116 $1,211.10 $100.85 $188.41 Herzuma (Cephalon) 3/31/2020 Q5113 $1,402.50 $746.33 $823.56 Ontruzant (Organon) 10/31/2021 Q5112 $1,324.66 $420.23 $502.68 *Includes Medicare sequestration
for Q2 2024 (150mg)
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
information
Product Launch Date HCPC WAC ASP Anticipated Medicare Reimbursement* Biologic Herceptin (Genentech) N/A N/A N/A N/A N/A Biosimilars Ogivri (Biocon) 12/31/2019 Q5114 $2,625.05 $2,376.22 $2,587.88 Kanjinti (Amgen) 6/30/2019 Q5117 $3,808.18 $488.86 $730.72 Trazimera (Pfizer) 3/31/2020 Q5116 $3,391.08 $282.39 $527.55 Herzuma (Cephalon) 4/30/2020 Q5113 $3,927.00 $2,089.74 $2,305.98 Ontruzant (Organon) 10/31/2021 Q5112 $3,709.04 $1,176.66 $1,407.51 *Includes Medicare sequestration
Reimbursement
for Q2 2024 (420mg)
Historical ASPs
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
$0 $200 $400 $600 $800 $1,000 $1,200 $1,400 $1,600 Q12019 Q22019 Q32019 Q42019 Q12020 Q22020 Q32020 Q42020 Q12021 Q22021 Q32021 Q42021 Q12022 Q22022 Q32022 Q42022 Q12023 Q22023 Q32023 Q42023 Q12024 Q22024
Herceptin (Genentech) Ogivri (Biocon) Kanjinti (Amgen) Trazimera (Pfizer) Herzuma (Cephalon) Ontruzant (Organon)
Average Change of ASP
This graph showcases the cumulative average change in the average sales price (ASP) for the Trastuzumab family, tracking changes from the launch of biosimilars to each quarter's ASP. It highlights the evolution of ASP over the product's lifecycle and the fluctuating rate of change, providing a concise overview of pricing dynamics.
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
-16% -14% -12% -10% -8% -6% -4% -2% 0% 2% 4% Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024
Herceptin (Genentech) Ogivri (Biocon) Kanjinti (Amgen) Trazimera (Pfizer) Herzuma (Cephalon) Ontruzant (Organon)
WAC* vs. Initial ASPs
*Refers to the WAC when the first ASP was released
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
-51.9% 35.1% -6.7% -4.3% -3.2% -3.6% -51.9% 35.2% -6.6% -4.2% -8.2% -1.9% -51.0% 39.6% -16.2% -4.1% -13.7% -6.6% $0 $200 $400 $600 $800 $1,000 $1,200 $1,400 $1,600 $1,800
Herceptin (Genentech)
Ogivri (Biocon)
Kanjinti (Amgen)
Trazimera (Pfizer)
Herzuma (Cephalon)
Ontruzant (Organon)
WAC First ASP Second ASP Third ASP
ASP Percent Change from WAC*
*Refers to the WAC when the first ASP was released
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
-100% -80% -60% -40% -20% 0% 20% 40% 60% Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024
Herceptin (Genentech) Ogivri (Biocon) Kanjinti (Amgen) Trazimera (Pfizer) Herzuma (Cephalon) Ontruzant (Organon)
Aria ASP predictive model
In line with Aria's goal to provide key insights to our members, our analytics team has developed a proprietary predictive ASP model for the Trastuzumab product family.
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
$0 $200 $400 $600 $800 $1,000 $1,200 $1,400 $1,600 Q12019 Q22019 Q32019 Q42019 Q12020 Q22020 Q32020 Q42020 Q12021 Q22021 Q32021 Q42021 Q12022 Q22022 Q32022 Q42022 Q12023 Q22023 Q32023 Q42023 Q12024 Q22024Q32024Predicted
Herceptin (Genentech) Ogivri (Biocon) Kanjinti (Amgen) Trazimera (Pfizer) Herzuma (Cephalon) Ontruzant (Organon)
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential. Thank you. www.ariagpo.com info@ariagpo.com